A Randomized, Double-blind, Active and Placebo-controlled, Study of SPARC1401 in Subjects With Moderate to Severe Acute Low Back Pain
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Tizanidine (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 14 Dec 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 14 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 14 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.